Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The Israeli pharma paid $10 million to collaborate with Heptares on CGRP antagonists but has bailed before the first program hit the clinic.
We started the Rotten Tomatoes special feature last year to spotlight companies that haven't followed through on the tough ethical and scientific demands…
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
The four-year alliance tasks Vividion with discovering drugs that interact with the ubiquitin proteasome system cells used to break proteins apart.
Boston biotech FDNA is creating a consortium that will try to apply artificial intelligence and machine learning to the development of new medicines.
The collaboration will apply Pelago’s cellular assay technology to the screening and safety assessment of assets in AstraZeneca’s pipeline.
GeneTx will develop an antisense drug for Angelman syndrome, a genetic disorder that affects the nervous system.
Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.
The French biopharma follows Fosun, Takeda and UCB to become the fourth company to secure a connection to Arix’s stable of startups.
Ionis could pick up $300 million in milestones and royalties as well as the $30 million licensing fee.
Roivant and Arbutus have a month to decide if they're going to set up a new company for RNA delivery.